Company Profile
Allarity Therapeutics Stock Price, News & Analysis
- Ticker:
- ALLR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Denmark
Stock performance
1.40 USD (+5.26%)
Close
Last updated: August 6, 2026
26.9M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ALLR closed up 5.26% at $1.40. No new same-company headline was identified in the current news window.
Company overview
Stenoparib-Focused Oncology Company
Allarity Therapeutics is a Phase 2 clinical-stage company developing stenoparib/2X-121, an oral dual inhibitor of PARP1/2 and tankyrase 1/2. The program is focused on advanced ovarian cancer and relapsed small cell lung cancer.
DRP Companion Diagnostic Strategy
Allarity uses its Drug Response Predictor companion diagnostic to identify patients most likely to benefit from stenoparib. The company has received a Notice of Allowance for a U.S. patent application covering the stenoparib-specific DRP diagnostic.
Ovarian Cancer Strategy
Stenoparib is advancing in platinum-resistant or platinum-ineligible ovarian cancer under FDA Fast Track designation. The DRP diagnostic is intended to enrich the study population for patients more likely to respond.
Small Cell Lung Cancer Combination
A VA-funded study is evaluating stenoparib with temozolomide in relapsed small cell lung cancer. This program extends the asset from biomarker-guided monotherapy into a combination-treatment setting.
Future catalysts
A manufacturing campaign for Phase 3-ready stenoparib active pharmaceutical ingredient is expected to be completed in the third quarter of 2026.
Enrollment has begun in the VA-funded trial of stenoparib plus temozolomide in relapsed SCLC, with future clinical data representing the next program milestone.
An amended Phase 2 protocol in platinum-resistant or platinum-ineligible ovarian cancer began enrolling in summer 2025, and subsequent data will inform the potential FDA approval path.
Recent news
- 01
- 02
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic
Source: Allarity Therapeutics
- 03
- 04
Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers
Source: Allarity Therapeutics
- 05
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
Source: Allarity Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Allarity Therapeutics (ALLR)?
Allarity Therapeutics (ALLR) most recently closed at 1.40 USD, a +5.26% move versus the previous session.
What is the market cap of Allarity Therapeutics (ALLR)?
Allarity Therapeutics currently has a market capitalization of 26.9M USD on BioPharmSignal.
What does Allarity Therapeutics do?
Stenoparib-Focused Oncology Company Allarity Therapeutics is a Phase 2 clinical-stage company developing stenoparib/2X-121, an oral dual inhibitor of PARP1/2 and tankyrase 1/2. The program is focused on advanced ovarian cancer and relapsed small cell lung cancer. DRP Companion Diagnostic Strategy Allarity uses its Drug Response Predictor companion...
On which exchange is ALLR stock listed?
Allarity Therapeutics (ALLR) is associated with NASDAQ, Denmark, Biopharma.
What is stenoparib?
A manufacturing campaign for Phase 3-ready stenoparib active pharmaceutical ingredient is expected to be completed in the third quarter of 2026.
Which conditions is Allarity Therapeutics targeting with stenoparib?
Allarity Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Allarity Therapeutics describe recent progress with stenoparib?
A manufacturing campaign for Phase 3-ready stenoparib active pharmaceutical ingredient is expected to be completed in the third quarter of 2026.
What is Stenoparib-Focused?
Stenoparib-Focused Oncology Company Allarity Therapeutics is a Phase 2 clinical-stage company developing stenoparib/2X-121, an oral dual inhibitor of PARP1/2 and tankyrase 1/2.